Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics has appointed James Loerop as Chief Business Officer, effective January 31, 2022. Loerop brings over two decades of experience in business development, most recently serving as Executive Vice President at Anika Therapeutics. His expertise is expected to enhance Aclaris' global business development strategy for its drug pipeline targeting immuno-inflammatory diseases. Additionally, John Schindler, Ph.D., has been named Senior Director of Discovery Research, focusing on early-stage targets.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced updates on its clinical programs and R&D operations as of January 11, 2022. Two Phase 2 studies of Zunsemetinib for rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) are underway, aiming to evaluate efficacy and optimal dosing. Additionally, the company has initiated a first-in-human Phase 1 trial of ATI-2138, targeting T-cell mediated autoimmune diseases. Notably, Aclaris has strengthened its R&D team and is planning to fill key leadership positions following the departure of Chief Medical Officer David Gordon.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, announced participation by Dr. Neal Walker, its President and CEO, in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference. The event will be available starting January 10, 2022, at 7:00 a.m. ET, and interested parties can access the webcast through the "Events" page on Aclaris' website. The company is focused on developing innovative drug candidates for immuno-inflammatory diseases, addressing significant unmet medical needs.
Aclaris Therapeutics (NASDAQ: ACRS) announced the publication of preclinical research on zunsemetinib in pancreatic cancer in the journal Science Translational Medicine on December 1, 2021. This study, conducted in collaboration with Washington University School of Medicine, identifies the MK2/HSP27 axis as a key survival mechanism for pancreatic cancer cells under chemotherapy stress. Results showed that zunsemetinib significantly increased mouse survival when combined with FOLFIRINOX therapy. Aclaris is considering advancing this research into clinical trials for pancreatic cancer treatment.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the FDA has allowed its Investigational New Drug (IND) application for ATI-2138, an oral ITK/TXK/JAK3 inhibitor aimed at treating psoriasis. The company is set to provide more details on this and other drug candidates during a virtual R&D Day on December 7, 2021. Topics will include ATI-450 and ATI-2231, both MK2 inhibitors, and an Oral Gut-restricted Discovery Program. Participation in this event can be accessed via conference call or webcast from Aclaris’ website.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced participation in two upcoming investor conferences. Dr. Neal Walker, President and CEO, will engage in a virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. Additionally, he will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. Virtual one-on-one meetings will also be available. Live webcasts can be accessed via Aclaris’ website, and recordings will be archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported a net loss of $21.1 million for Q3 2021, compared to $10.7 million in Q3 2020, with total revenue of $1.7 million, up from $1.4 million year-over-year. R&D expenses surged to $14.0 million, influenced by efforts to advance zunsemetinib, an investigational drug for rheumatoid arthritis. The company holds $243.6 million in cash and equivalents, projected to sustain operations through 2024. Additionally, an investigational new drug application for ATI-2138 was submitted, marking potential expansion in immuno-inflammatory treatments.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced a Settlement Hearing set for November 30, 2021, regarding the Consolidated Derivative Action in the U.S. District Court for the Southern District of New York. Judge Lewis J. Liman granted preliminary approval for the settlement on August 18, 2021, which includes corporate governance reforms and attorneys' fees paid by Aclaris' insurer. Stockholders can object to the Proposed Settlement until November 16, 2021. Final approval from the Court is not assured.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol ACRS, announced their participation in two upcoming investor conferences. Dr. Neal Walker, President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, and at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021. Both events will include opportunities for virtual one-on-one meetings. Webcasts of the presentations will be available on the Aclaris website for 30 days.
Aclaris Therapeutics (ACRS) reported a net loss of $18.2 million for Q2 2021, an increase from $11.6 million in Q2 2020. Total revenue reached $1.8 million, slightly down from $2.0 million a year earlier. R&D expenses rose to $7.9 million, driven by development of ATI-450 and ATI-2138. The company successfully secured $134.9 million in net proceeds from a public offering in June, allowing them to extend their cash runway through late 2024. Preliminary positive topline data for the Phase 2a trial of ATI-1777 in atopic dermatitis was also announced.